FDA Reviews, Acquisitions, Dividends, and Drug Study Results Highlight Solid Growth for Major Drug Companies - Research Report

 FDA Reviews, Acquisitions, Dividends, and Drug Study Results Highlight Solid
    Growth for Major Drug Companies - Research Report on Pfizer, Johnson &
                      Johnson, Zoetis, AbbVie, and Lilly

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 26, 2013

NEW YORK, June 26, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Zoetis Inc. (NYSE: ZTS),
AbbVie Inc. (NYSE: ABBV), and Eli Lilly and Company (NYSE: LLY). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On June 21, 2013, Pfizer Inc. (Pfizer) announced that the US Food and Drug
Administration (FDA) has accepted the review of a supplemental New Drug
Application (sNDA) for the XELJANZ (tofacitinib citrate) rheumatoid arthritis
(RA) indication. The sNDA seeks to expand the label to include inhibition of
progression of structural damage. Pfizer reported that XELJANZ 5mg twice daily
was approved by the US FDA in November 2012. The Company is expecting the US
FDA to conclude its review of the NDA and provide a decision by February 2014,
based on the anticipated Prescription Drug User Free Act (PDUFA) action date
for the sNDA. The Full Research Report on Pfizer Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Johnson & Johnson Research Report

On June 17, 2013, Johnson & Johnson announced that it has entered into a
definitive agreement for the acquisition of Aragon Pharmaceuticals, Inc.,
which is a privately-held, pharmaceutical discovery and development company
focused on drugs to treat hormonally-driven cancers. Johnson & Johnson
reported that the acquisition will include Aragon Pharmaceuticals' androgen
receptor antagonist program. Under the terms of the agreement, Johnson &
Johnson will make an upfront cash payment of $650 million, plus additional
contingent payments of up to $350 million based on certain predetermined
milestones. Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head,
Oncology for Janssen Research & Development, LLC, said, "The acquisition of
Aragon further enhances our leadership in prostate cancer drug development.
ARN-509 complements ZYTIGA and provides the potential for exciting, novel
approaches to treat prostate cancer patients." The Full Research Report on
Johnson & Johnson - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Zoetis Inc. Research Report

On June 20, 2013, Zoetis Inc. (Zoetis) announced that its Board of Directors
has declared the Q3 2013 dividend. The Board of Directors approved a quarterly
dividend of c.$0.07 per common share, which is payable on September 2, 2013 to
shareholders on record as of August 1, 2013. The Full Research Report on
Zoetis Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


AbbVie Inc. Research Report

On June 17, 2013, AbbVie Inc. (AbbVie) presented the preliminary results of
the Phase I study for ABT-199/GDC-0199, an investigational BCL-2 (B-cell
lymphoma 2) selective inhibitor, in patients with high-risk
relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with
relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 18th Congress of the
European Hematology Association (EHA) in Stockholm, Sweden. Gary Gordon, M.D.,
Divisional Vice President of Oncology Clinical Development at AbbVie, stated,
"The preliminary data presented at EHA further support the ongoing clinical
trial program for ABT-199/GDC-0199 via the BCL-2 pathway." Professor Andrew
Roberts, Hematologist at the Royal Melbourne Hospital and head of Clinical
Translation at the Walter and Eliza Hall Institute of Medical Research,
Melbourne, Australia, commented, "High-risk CLL patients are a challenging
subgroup to treat, as they tend to have disappointing results with
conventional chemotherapy regimens. While still early in the development
process, preliminary response rates observed in these patients appear similar
to those observed in other CLL patients being treated with ABT-199/GDC-0199.
These data justify further investigation of this compound in patients with 17p
deletion and fludarabine-refractory CLL." The Full Research Report on AbbVie
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:


Eli Lilly and Company Research Report

On June 22, 2013, Eli Lilly and Company (Lilly) announced the detailed safety
and efficacy results from three Phase III AWARD trials for dulaglutide, an
investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist
being studied as a once-weekly treatment for type 2 diabetes. Guillermo
Umpierrez, M.D., Professor of Medicine, Division of Endocrinology, Metabolism,
Emory University School of Medicine, and Chief of Diabetes and Endocrinology,
Grady Memorial Hospital, stated, "Dulaglutide not only demonstrated superior
glycemic control in these Phase III trials, it provided this control with
once-weekly dosing, which may be attractive to both patients and healthcare
professionals. It's encouraging news for this investigational GLP-1 receptor
agonist." Sherry Martin, M.D., Senior Medical Director, Lilly Diabetes added,
"These results are a promising step forward in our effort to provide a new,
once-weekly GLP-1 treatment option, giving patients another choice to help
manage their diabetes." The Full Research Report on Eli Lilly and Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.